Indianapolis-based Eli Lilly and Co. will team with German drugmaker Boehringer Ingelheim to develop diabetes treatments, as the U.S. pharmaceutical company pushes to fill a looming revenue gap created by expiring patents for several key drugs. Get the full story »
Inside these posts: Diabetes
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Abbott recalls millions of diabetes test strips
By Andrew Zajac
Abbott Laboratories Wednesday announced a recall of as many as 359 million glucose test strips used to monitor diabetics’ blood sugar because they may give falsely low readings.
The strips may not absorb enough blood quickly enough to give a proper reading, which can lead users to try to raise sugar levels unnecessarily, or to fail to treat elevated glucose levels, the company said in a statement. Get the full story »
FDA looks into diabetes drug, bladder cancer
The Food and Drug Administration said Friday that it has started a safety review of Takeda Pharmaceutical Co.’s diabetes drug Actos looking at links to bladder cancer.
The FDA said the review was prompted from preliminary, five-year data from an ongoing study involving the drug. The study, designed to follow patients for 10-years, is being funded by Takeda. Get the full story »
Success with wireless diabetes monitor reported
Researchers have developed an implantable sensor that measures blood sugar continuously and transmits the information without wires — a milestone, they said, in diabetes treatment.
The device worked in one pig for more than a year and in another for nearly 10 months with no trouble, said a report in the journal Science Translational Medicine. Get the full story »
FDA warns Abbott on glucose monitors
The U.S. Food and Drug Administration has warned Abbott Laboratories’ diabetes care unit about manufacturing problems at its Alameda, California plant, a letter released Tuesday said.
In a letter dated July 2, FDA said its inspectors found Abbott’s Freestyle and Navigator blood glucose monitoring products were adulturated and not conforming with codes for good quality system manufacturing practices. Get the full story »
July 13, 2010 at 12:22 p.m.
Comments Off
Filed under: Scientists debate fate of Avandia
FDA scientists debated how to interpret the outcome of a large clinical trial that GlaxoSmithKline PLC says backs the safety of its diabetes drug Avandia.
Avandia is currently being reviewed by a federal panel that is scheduled to vote Wednesday on whether it thinks Avandia should remain on the U.S. market. FDA Commissioner Margaret Hamburg opened the meeting Tuesday, telling advisers to “follow the science where ever it may lead and the rest will fall into place.” Get the full story »
Studies link diabetes drug Avandia with heart risks
Two studies released Monday reported serious heart risks with GlaxoSmithKline Plc diabetes pill Avandia as U.S. regulators decide whether the drug should stay on the market.
An analysis of 56 clinical trials found Avandia increased the chances of a heart attack by 28 percent to 39 percent, researchers at the Cleveland Clinic in Ohio reported in an update to a 2007 study that sparked intense debate about the drug. Get the full story »
